Conference
Event Title
23rd US-Japan Cellular and Gene Therapy Conference
March 12, 2020
- Date:
- March 12, 2020
- Time:
- 8:30 AM - 5:00 AM ET
- Location:
-
Event LocationFDA, White Oak Campus, The Great Room
Building 31
10903 New Hampshire Avenue
Silver Spring, MD 20903
United States
- Organized By:
Due to extenuating circumstances, this conference is being postponed until further notice.
Exosomes in Cancer Treatments and Other Diseases
FDA White Oak Campus, Building 31, Great Room, 1503 A
Silver Spring, Maryland 20993
Thursday, March 12, 2020
8:30 am – 5:00 pm
The annual US-Japan Cellular and Gene Therapy Conference will provide scientists from Japan and the U.S. a valuable opportunity to discuss the state of the art of exosome therapies and establish research collaborations.
The conference is jointly supported by the Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration (FDA), and the Ministry of Education, Culture, Sports, Science and Technology, Japan under the US-Japan Cooperative Research Program.
Exosomes are of immense biological interest due to their pleiotropic nature. These nanosized, single-membrane biovesicles are secreted by normal and diseased cells--including neoplastic cells--into blood and body fluids. They mediate intercellular communication by carrying different biomolecules, including proteins, lipids, and genetic materials, such as RNA. Exosomes appear to play roles in many physiological processes, such as cancer stemness, angiogenesis, metastasis, and immune response modulation. However, while several clinical studies of exosomes are underway, their quality attributes are not fully understood.
The speakers will discuss the mechanism of exosome biogenesis, molecular composition of exosomes, technologies used in exosomes isolation, mechanisms of action, and their translational potential. The program is designed to advance understanding of the therapeutic potential of exosomes and help to resolve the obstacles to their full clinical application.
No prior registration is required. Attendance is free and open to the public. For more information, please contact S. Rafat Husain at syed.husain@fda.hhs.gov or (240) 402-9598.
The event can be viewed live via Adobe Connect at https://collaboration.fda.gov/us-japan/. Click the link and enter as a guest. Driving directions and visitors parking information is available at
https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241748.htm
PROGRAM | ||
8:30 am – 9:00 am | Registration, Coffee and Breakfast | |
Moderator | S. Rafat Husain, Staff Scientist, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland | |
Opening Remarks | ||
9:00 am – 9:05 am | Peter Marks, Director, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland | |
9:05 am – 9:10 am | Yoshikazu Ohya, Professor, Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo | |
Morning Session | ||
Moderators | Akiko Takahashi, Project Leader, Project for Cellular Senescence, Cancer Institute, Japanese Foundation for Cancer Research / PRESTO, JST Saitama Japan, PRIME, AMED, Tokyo, Japan | |
Raj K. Puri, Director, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland | ||
9:10 am – 9:40 am |
The biology of cellular senescence and small extracellular vesicles |
|
9:40 am – 10:10 am |
Exosome biogenesis and exosome engineering |
|
10:10 am – 10:30 am | Coffee Break | |
10:30 am – 11:00 am |
Hippo pathway in cancer and immunity |
|
11:00 am – 11:30 am |
Circadian variation in urine exosome excretion: implications for biomarker normalization |
|
11:30 am – 12:00 pm |
Early-stage cancer diagnoses using microRNA ensemble biomarkers in urine |
|
12:00 pm – 1:00 pm | Lunch | |
Afternoon Session | ||
Moderators | Takahiko Tokuda, Professor, Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan | |
Lance Liotta, Co-Director and Co-Founder, Center for Applied Proteomics and Molecular Medicine, School of Systems Biology, George Mason University Virginia, Fairfax, Virginia | ||
1:00 pm – 1:30 pm |
Engineering EVs to reverse cancer immune evasion at the level of the sentinel lymph node |
|
1:30 pm – 2:00 pm |
Exosomes as double-edged sword for cancer metastasis promotion |
|
2:00 pm – 2:30 pm |
Damage and Repair: How "Bad EVs" from infections cause death and "Good EVs" from Stem cells do repair |
|
2:30 pm – 2:50 pm | Coffee Break | |
2:50 pm – 3:20 pm |
Development of blood-based biomarkers for neurodegenerative diseases |
|
3:20 pm – 3:50 pm |
Engineering extracellular vesicle potency and production for therapeutic applications |
|
3:50 pm – 4:20 pm |
Propagation of TDP-43 as a key factor of disease progression of amyotrophic lateral sclerosis |
|
4:20 pm - 4:50 pm |
Developing a toolset to characterize EVs in a translational setting |
|
Thank you for your participation! | ||
Organizers: |
S. Rafat Husain, Ph.D. |
Yoshikazu Ohya, Ph.D. Professor, Division of Biosciences Department of Integrated Biosciences Graduate School of Frontier Sciences University of Tokyo Bldg. FSB-101, 5-1-5 Kashiwanoha Kashiwa, Chiba Prefecture 277-8562 Japan ohya@k.u-tokyo.ac.jp |
Cover Image: Exosomes secreted by cancer cells. Source: Cancer Research from Technology Networks |